Dilaudid: payments to doctors
Payments that named Dilaudid as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
Was your doctor paid by Fresenius Kabi USA, LLC?
Fresenius Kabi USA, LLC reported the most payments naming Dilaudid. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $55K
- Providers
- 16
- Transactions
- 31
- Average per transaction
- $1,761
The per-transaction average — $1,761 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 16 providers the average total is $3,413, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Fresenius Kabi USA, LLC | $54,604 | 100.0% |
Other products from Fresenius Kabi USA, LLC
The company that reported the most payments naming Dilaudid also reports against these.
- Omegaven$3,264,201
- Smoflipid$551,185
- Idacio$382,430
- MD-Other$154,765
- Stimufend$116,742
- MD-Amicus$92,859
- PH-Omegaven$92,378
- Amicus Separator$79,606
- PH-Icatibant$64,767
- Ivenix Infusion System$58,836